Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03170388 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris
A Phase 2 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 741
- Enrollment target
NCT03170388: Completed Phase 2 study, sponsored by Bausch Health Americas.
NCT03170388 is a Phase 2 study that has completed, run by Bausch Health Americas. The registered enrollment target is 741 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (457% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03170388, a Phase 2 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 741 participants
- Enrollment target
Study Summary
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris
Primary Outcome
Absolute change from Baseline to Week 12 in mean inflammatory lesion counts
Interventions
- DRUG IDP-126 Gel
- DRUG IDP-126 Vehicle Gel
- DRUG IDP-126 Component A
- DRUG IDP-126 Component B
- DRUG IDP-126 Component C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 741 participants |
| Start Date | 2017-10-05 |
| Est. Completion | 2019-04-23 |
| Phase | Phase 2 |
What the finished NCT03170388 record still lists
NCT03170388 is an interventional study that assigns participants to a tested intervention. The registered 741 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (457% higher).
The record links to 0 conditions, and to 5 interventions - of which IDP-126 Gel is the first listed.
NCT03170388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03170388 about?
NCT03170388 is a clinical study titled "A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris". A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris
What is the current status of trial NCT03170388?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 741 participants. The study started on 2017-10-05. Estimated completion is 2019-04-23.
What interventions are being tested in trial NCT03170388?
The interventions under investigation include: IDP-126 Gel (DRUG), IDP-126 Vehicle Gel (DRUG), IDP-126 Component A (DRUG), IDP-126 Component B (DRUG), IDP-126 Component C (DRUG).
Who is sponsoring clinical trial NCT03170388?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03170388's enrollment target sits among peer trials
741 44th of 2000 higher than 1,957 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786417 · 741 participants · Phase 4
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
- NCT06556563 · 741 participants · Phase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI